HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].

Abstract
Twenty-one patients with hematopoietic malignancies including 6 previously untreated, 9 pretreated, and in relapse, 5 in complete remission and one in partial remission all were treated with PL-AC. The patients consisted of 12 acute myelocytic leukemias, 4 acute monocytic leukemias, 2 acute lymphocytic leukemias, one erythroleukemia, one malignant lymphoma and one chronic monocytic leukemia. PL-AC was given orally at a dosage of 50-1200 mg daily. Mean total dosage was 4.74 g (0.6-15.25), and the mean administration period was 3.43 days (1-122). days Responses were observed in 4 out of 9 pretreated patients by a decrease of blast cells in the peripheral blood. Partial remission was obtained in one case which lasted 8 months. Out of 5 previously untreated acute leukemias, one partial remission and 4 hematological responses were observed. The plasma concentration of Ara-C was maximal at 3 hours and was not detectable after 12 hours. Side effects observed were nausea in 5 patients vomiting in one patient and liver dysfunction in one patient. These side effects however were not so severe as to stop drug administration. PL-AC may be administered in doses ranged 150-250 mg for 2-3 weeks without any severe side effects, and with some clinical effects.
AuthorsT Takubo, Y Kubota, T Tanaka, T Ueda, H Shibata, H Nakamura, T Masaoka, J Yoshitake, S Ishigami
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 10 Issue 2 Pt Pg. 283-9 (Feb 1983) ISSN: 0385-0684 [Print] Japan
PMID6576729 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cytarabine
  • 5'-palmitoyl cytarabine
Topics
  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, metabolism, therapeutic use)
  • Child
  • Cytarabine (administration & dosage, analogs & derivatives, metabolism, therapeutic use)
  • Drug Evaluation
  • Female
  • Humans
  • Leukemia, Monocytic, Acute (drug therapy)
  • Leukemia, Myeloid, Acute (drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: